Clinical studies indicate that addition of bupropion to selective serotonin (5-HT) reuptake inhibitors (SSRIs) provides incremental benefit over SSRI monotherapy in depression. This study was designed to investigate the effects of co-administration of bupropion with escitalopram on the firing rate of 5-HT and norepinephrine (NE) neurons in anesthetized rats. Escitalopram (10 mg/kg/day × 2 days), given via subcutaneously (s.c.) implanted minipumps, decreased the firing of 5-HT and NE neurons by 70% and 55%, respectively. The firing of 5-HT neurons, unlike that of NE neurons, recovered after the 14-day escitalopram regimen. Bupropion, injected once daily (30 mg/kg/day, s.c. × 2 days), did not increase 5-HT firing but decreased that of NE by 55%. After 14 days of repeated bupropion administration, 5-HT firing was increased by 50%, and NE firing was back to baseline. Co-administration of escitalopram and bupropion doubled 5-HT firing after 2 and 14 days, whereas NE neurons were inhibited by 60% after 2 days, but partially recovered after 14 days. The responsiveness of 5-HT1A autoreceptors was significantly attenuated in the combination-treated rats after 2 days, indicating an early desensitization. These results provide support for contributions from 5-HT and NE mechanisms for enhanced effectiveness of combination of SSRI and bupropion treatment.
Albert, PR, Lemonde, S. ( 2004) 5-HT1A receptors, gene repression, and depression: guilt by association. Neuroscientist10: 575-593.
2.
Aman, TK, Shen, RY, Haj-Dahmane, S. ( 2007) D2-like dopamine receptors depolarize dorsal raphe serotonin neurons through the activation of nonselective cationic conductance. J Pharmacol Exp Ther320: 376-385.
3.
Argyelan, M., Szabo, Z., Kanyo, B., Tanacs, A., Kovacs, Z., Janka, Z., et al. (2005) Dopamine transporter availability in medication free and in bupaopion treated depression: a 99mTc-TRODAT-1 SPECT study. J Affect Disord89: 115-123.
4.
Blier, P., de Montigny, C. ( 1983) Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat. J Neurosci3: 1270-1278.
5.
Blier, P., de Montigny, C. ( 1985) Serotoninergic but not noradrenergic neurons in rat central nervous system adapt to long-term treatment with monoamine oxidase inhibitors . Neuroscience16: 949-955.
6.
Blier, P., de Montigny, C. ( 1987a) Short-term lithium treatment enhances responsiveness of postsynaptic 5-HT1A receptors without altering 5-HT autoreceptor sensitivity: an electrophysiological study in the rat brain. Synapse1: 225-232.
7.
Blier, P., de Montigny, C. ( 1987b) Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain . Synapse1: 470-480.
8.
Blier, P., de Montigny, C., Tardif, D. ( 1984) Effects of the two antidepressant drugs mianserin and indalpine on the serotonergic system: single-cell studies in the rat. Psychopharmacology (Berl) 84: 242- 249.
9.
Chaput, Y., de Montigny, C., Blier, P. ( 1986) Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch Pharmacol333: 342-348.
10.
Cusack, B., Nelson, A., Richelson, E. ( 1994) Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology ( Berl) 114: 559-565.
11.
Daly, JJ, Prudic, J., Devanand, DP, Nobler, MS, Lisanby, SH, et al. (2001) ECT in bipolar and unipolar depression: differences in speed of response. Bipolar Disord3: 95-104.
12.
Dawe, GS, Huff, KD, Vandergriff, JL, Sharp, T., O’Neill, MJ, Rasmussen, K. ( 2001) Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-Fos immunoreactivity. Biol Psychiatry50: 510-520.
13.
DeBattista, C. ( 2006) Augmentation and combination strategies for depression . J Psychopharmacol20: 11-18.
14.
Dong, J., Blier, P. ( 2001) Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl) 155: 52-57.
15.
Dremencov, E., El Mansari, M., Blier, P. ( 2007) Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry61: 671-678.
16.
El Mansari, M., Sanchez, C., Chouvet, G., Renaud, B., Haddjeri, N. ( 2005) Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology30: 1269-1277.
17.
Gartside, SE, Hajos-Korcsok, E., Bagdy, E., Harsing, LG, Sharp, T., Hajos, M. ( 2000) Neurochemical and electrophysiological studies on the functional significance of burst firing in serotonergic neurons. Neuroscience98: 295-300.
18.
Gobbi, G., Slater, S., Boucher, N., Debonnel, G., Blier, P. ( 2003) Neurochemical and psychotropic effects of bupropion in healthy male subjects. J Clin Psychopharmacol23: 233-239.
19.
Grace, AA, Bunney, BS ( 1984) The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci4: 2877-2890.
20.
Guiard, BP, El Mansari, M., Merali, Z., Blier, P. ( 2008) Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol11: 625-639.
21.
Hajos, M., Sharp, T. ( 1996) Burst-firing activity of presumed 5-HT neurones of the rat dorsal raphe nucleus: electrophysiological analysis by antidromic stimulation . Brain Res740: 162-168.
22.
Hardebo, JE ( 1992) Influence of impulse pattern on noradrenaline release from sympathetic nerves in cerebral and some peripheral vessels. Acta Physiol Scand144: 333-339.
23.
Hensler, JG ( 2003) Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci72: 1665-1682.
24.
Kugaya, A., Seneca, NM, Snyder, PJ, Williams, SA, Malison, RT, Baldwin, RM, et al. (2003) Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology28: 413-420.
25.
Learned-Coughlin, SM, Bergstorm, M., Savitcheva, I., Ascher, J., Schmith, VD, Langstorm, B. ( 2003) In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry54: 800-805.
26.
Li, SX, Perry, KW, Wong, DT ( 2002) Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology42: 181-190.
27.
Marwaha, J., Aghajanian, GK ( 1982) Relative potencies of α1 and α2 antagonists in the locus ceruleus, dorsal raphe and dorsal lateral geniculate nuclei: an electrophysiological study. J Pharmacol Exp Ther222: 287-293.
28.
Meyer, JH, Goulding, VS, Wilson, AA, Hussey, D., Christensen, BK, Houle, S. ( 2002) Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology ( Berl) 163: 102-105.
29.
Millan, MJ, Rivet, JM, Gobert, A., Canton, H., Veiga, S., Bervoets, K. ( 1994) 5-HT1A receptors and the tail-flick response. VI. Intrinsic α1A-adrenoceptor antagonist properties can mask the actions of 5HT1A receptor agonists in the spontaneous tail-flick paradigm. J Pharmacol Exp Ther269: 121-131.
30.
Mischoulon, D., Nierenberg, AA, Kizilbash, L., Rosenbaum, JF, Fava, M. ( 2000) Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry45: 476-481.
31.
Mork, A., Kreilgaard, M., Sanchez, C. ( 2003) The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats . Neuropharmacology45: 167-173.
32.
Owens, MJ, Knight, DL, Nemeroff, CB ( 2001) Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry50: 345-350.
33.
Piacentini, MF, Clinckers, R., Meeusen, R., Sarre, S., Ebinger, G., Michotte, Y. ( 2003) Effect of bupropion on hippocampal neurotransmitters and on peripheral hormonal concentrations in the rat. J Appl Physiol95: 652-656.
34.
Pineyro, G., Blier, P. ( 1999) Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev51: 533-591.
35.
Seager, MA, Huff, KD, Barth, VN, Phebus, LA, Rasmussen, K. ( 2004) Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity. Biol Psychiatry55: 1103-1109.
36.
Stewart, JW ( 2007) Combined bupropion-escitalopram as first-line treatment for depression. Biol Psychiatry61 (Suppl. 8): 629.
37.
Svensson, TH, Bunney, BS, Aghajanian, GK ( 1975) Inhibition of both noradrenergic and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine. Brain Res92: 291-306.
38.
Szabo, ST, Blier, P. ( 2000) Effect of accute and sustained administration of reboxetine on locus coeruleus noradrenergic and dorsal 5-HT neurons. Int J neuropsychopharmacol3: S218-S219.
39.
Szabo, ST, Blier, P. ( 2001) Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons. Eur J Neurosci13: 2077-2087.
40.
Szabo, ST, Blier, P. ( 2002) Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT2A receptor antagonism on the firing activity of norepinephrine neurons. J Pharmacol Exp Ther302: 983-991.
41.
Szabo, ST, de Montigny, C., Blier, P. ( 1999) Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. Br J Pharmacol126: 568-571.
42.
Tatsumi, M., Groshan, K., Blakely, RD, Richelson, E. ( 1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol340: 249-258.
43.
Thase, ME, Entsuah, AR, Rudolph, RL ( 2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry178: 234-241.
44.
Trivedi, MH, Fava, M., Wisniewski, SR, Thase, ME, Quitkin, F., Warden, D., et al. (2006) Medication augmentation after the failure of SSRIs for depression. N Engl J Med354: 1243-1252.
